Here are seven new drug shortages and discontinuations, according to drug supply databases from the FDA and the American Society of Health-System Pharmacists.
- Azithromycin injection: Hospira has discontinued its 500-milligram, single-dose vial presentation of azithromycin injections, an anti-infective used to treat various bacterial infections. The discontinuation is due to the manufacturer ceasing production.
- Homatropine methylbromide and hydrocodone bitartrate syrup: Teva Pharmaceuticals has discontinued Hydromet syrup, an analgesia/addiction drug containing 1.5 milligrams of homatropine methylbromide and 5 milligrams of hydrocodone bitartrate in 5 millimeters.
- Hydroxocobalamin solution for intramuscular injection: Hydroxocobalamin intramuscular injection, used to treat vitamin B12 deficiency is in shortage. Teva, the sole supplier, has its 1,000-microgram/milliliter, 30-milliliter vials on backorder. No resupply date has been provided.
- Oxycodone hydrochloride oral solution: Hikma Pharmaceuticals has permanently discontinued the 15-milliliter bottle configuration of oxycodone hydrochloride oral solution, a medication used for pain management. The 5-milligram/5-milliliter strength remains available in the 500-milliliter bottle.
- Sumatriptan nasal spray: Prasco Laboratories has discontinued both strengths of sumatriptan nasal spray, a neurology drug used for migraine treatment. The 20 milligram/100 microliter will be distributed through Feb. 8. The discontinuation is due to a business decision.
- Vancomycin hydrochloride injection: Hospira has discontinued two presentations of vancomycin hydrochloride injection, an anti-infective medication. The affected strengths are the 1-gram and 750-milligram single-dose glass vials. The manufacturer has ceased production of both presentations.
- Vecuronium bromide injection: Sun Pharmaceuticals has discontinued its 20-milligram presentation of vecuronium bromide injection, an anesthesia drug. The 10-milligram strength remains available on the market.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
